Tonix Pharmaceuticals Holding (TNXP) Accumulated Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 157.01% year-over-year to $19.8 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 157.01% increase from a year earlier, with the FY2025 full-year figure at $22.6 million, up 111.85% from the prior year.
• Accumulated Expenses fell to $19.8 million in Q1 2026 per TNXP's latest filing, from $22.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $22.6 million in Q4 2025 and bottomed at $33000.0 in Q2 2024.
• The 5-year median for Accumulated Expenses is $9.7 million (2022), against an average of $10.0 million.
• Across the five-year window, Accumulated Expenses slumped 99.68% in 2024 and surged 33484.85% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $9.7 million in 2022, then rose by 28.95% to $12.5 million in 2023, then decreased by 14.54% to $10.7 million in 2024, then jumped by 111.85% to $22.6 million in 2025, then retreated by 12.22% to $19.8 million in 2026.
• Per Business Quant, the three latest TNXP Accumulated Expenses figures stand at $19.8 million (Q1 2026), $22.6 million (Q4 2025), and $12.3 million (Q3 2025).